Logotype for Fleury S.A.

Fleury (FLRY3) Q3 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Fleury S.A.

Q3 2024 earnings summary

14 Jul, 2026

Executive summary

  • Gross revenue reached R$2.13 billion in 3Q24, up 6.1% year-over-year, with EBITDA of R$537.4 million (6.2% growth) and net income of R$190.7 million (9.5% growth), reflecting strong execution and integration of Grupo Pardini and Hermes Pardini, and expansion in B2B and mobile services.

  • Consolidated net revenue for the nine months ended September 30, 2024, was R$5.85 billion, up 22.7% year-over-year, driven by organic growth, acquisitions (São Lucas, Gênesis JV), and new business lines.

  • Net income attributable to shareholders was R$532.3 million for the nine months, a 55.4% increase year-over-year, reflecting improved operational performance and scale.

  • The company maintained a robust capital structure, with a leverage ratio of 1.0x net debt/EBITDA and extended debt maturity to 3.4 years.

  • Multiple industry awards and recognition reinforce leadership in the Brazilian healthcare sector.

Financial highlights

  • Gross revenue: R$2.13 billion (+6.1% YoY) in 3Q24; net revenue: R$1.96 billion (+5.0% YoY); EBITDA: R$537.4 million (+6.2% YoY), margin 27.4% (+32 bps); net income: R$190.7 million (+9.5% YoY), margin 9.7% (+40 bps).

  • Gross profit for 3Q24 was R$557.0 million (+5.6% YoY), gross margin 28.4% (+17 bps); operating income before financial results and taxes was R$996.8 million for the nine months (+36.4% YoY).

  • Operational cash flow in 3Q24 was R$558.7 million (+16.2% YoY); capex: R$112.7 million (+29.1% YoY), focused on IT/digital and technical areas.

  • Net debt stood at R$1.87 billion, net debt/EBITDA at 1.0x, with average debt maturity of 3.4 years and recent debenture issuance extending average term to 4.2 years at CDI +0.95%.

  • Earnings per share (basic and diluted) for the nine months were R$0.98, compared to R$0.71 in the prior year.

Outlook and guidance

  • Management expects continued disciplined execution, innovation, and digital evolution, with a focus on expanding B2B Lab-to-Lab, digital health platforms, and new regions.

  • Integration with Pardini Group progressing, with further synergies expected in technical platforms and supplier contracts.

  • No formal guidance provided, but management expects ongoing resiliency and growth opportunities, especially in intermediate segments and mobile services.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more